What SEC filings does Vera Therapeutics, Inc. submit to the SEC?

Vera Therapeutics, Inc. (VERA) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about VERA?

A Form 4 for VERA discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Vera Therapeutics, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for VERA?

The 10-K is Vera Therapeutics, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all VERA SEC filings directly on EDGAR?

You can view all historical Vera Therapeutics, Inc. filings on the SEC EDGAR company page for VERA. Each filing card on this page links directly to the original SEC document.

How often does Vera Therapeutics, Inc. file with the SEC?

Vera Therapeutics, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling VERA shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

VERA SEC Filing News — Vera Therapeutics, Inc.

Latest SEC filings for Vera Therapeutics, Inc. (VERA) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-17.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune…

Sector: Healthcare Industry: Biotechnology Market Cap: $2.1B CIK: 1831828

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for VERA currently lean bearish. Of the 20 filing records displayed, 4 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

VERA Filing Activity Snapshot 2026-05-26 — 2026-09-17

Insider Transactions (Form 4)

0 buys vs 4 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$2.84M

MARSHALL FORDYCE · 2026-06-23

74,000 shares · Form 144

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Vera Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 6 compensation award, 4 open-market sale and 1 option exercise. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×6: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×4: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Option exercise ×1: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Form 4 Open-market sale Insider Selling 2026-09-17

VERA insider Fordyce Marshall (Director, PRESIDENT AND CEO) sold 18,500 shares (~$684.5K)

Fordyce Marshall, listed as Director, PRESIDENT AND CEO at Vera Therapeutics, Inc., reported an open-market sale of 18,500 VERA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	18,500	$2.90	$53.6K
`S`	Open-market sale	18,500	$37.00	$684.5K
`M`	Option exercise derivative · Stock Option (Right to Buy)	18,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Fordyce Marshall (Director, PRESIDENT AND CEO) Shares: 18,500 Est. Value: $684.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-09-14

VERA insider Form 4 filed for equity award, exercise, or tax withholding

Young Joseph R (SVP, FINANCE, CHIEF ACCT OFFCR) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	5,000	$3.94	$19.7K
`M`	Option exercise derivative · Stock Option (right to buy)	5,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Young Joseph R (SVP, FINANCE, CHIEF ACCT OFFCR) Shares: 5,000

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-04

VERA insider Fordyce Marshall (Director, PRESIDENT AND CEO) sold 18,500 shares (~$649.6K)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	18,500	$2.90	$53.6K
`S`	Open-market sale	18,500	$35.12	$649.6K
`M`	Option exercise derivative · Stock Option (Right to Buy)	18,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Fordyce Marshall (Director, PRESIDENT AND CEO) Shares: 18,500 Est. Value: $649.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-05

VERA insider Form 4 filed for equity award, exercise, or tax withholding

Boman Nancy Lee (Chief Regulatory Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	44,987	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	63,011	—	—

Filing: Form 4 (Insider Transaction) Insider: Boman Nancy Lee (Chief Regulatory Officer) Shares: 44,987

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-09

VERA insider Fordyce Marshall (Director, PRESIDENT AND CEO) sold 46,250 shares (~$1.96M)

Fordyce Marshall, listed as Director, PRESIDENT AND CEO at Vera Therapeutics, Inc., reported an open-market sale of 46,250 VERA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,000	$40.78	$40.8K
`S`	Open-market sale	32,550	$42.07	$1.37M
`S`	Open-market sale	10,500	$42.86	$450.0K
`S`	Open-market sale	2,200	$43.59	$95.9K

Filing: Form 4 (Insider Transaction) Insider: Fordyce Marshall (Director, PRESIDENT AND CEO) Shares: 46,250 Est. Value: $1.96M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-24

VERA insider Fordyce Marshall (Director, PRESIDENT AND CEO) sold 18,500 shares (~$701.8K)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	18,412	$37.93	$698.4K
`S`	Open-market sale	88	$38.43	$3.4K

Filing: Form 4 (Insider Transaction) Insider: Fordyce Marshall (Director, PRESIDENT AND CEO) Shares: 18,500 Est. Value: $701.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-26

VERA insider Form 4 filed for equity award, exercise, or tax withholding

Morrison Scott W (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	17,084	—	—

Filing: Form 4 (Insider Transaction) Insider: Morrison Scott W (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-26

VERA insider Form 4 filed for equity award, exercise, or tax withholding

Cheng Andrew (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	17,084	—	—

Filing: Form 4 (Insider Transaction) Insider: Cheng Andrew (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-26

VERA insider Form 4 filed for equity award, exercise, or tax withholding

SEIDENBERG BETH C (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	17,084	—	—

Filing: Form 4 (Insider Transaction) Insider: SEIDENBERG BETH C (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-26

VERA insider Form 4 filed for equity award, exercise, or tax withholding

Oliger Christy J. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	17,084	—	—

Filing: Form 4 (Insider Transaction) Insider: Oliger Christy J. (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-26

VERA insider Form 4 filed for equity award, exercise, or tax withholding

Meyers James R (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	17,084	—	—

Filing: Form 4 (Insider Transaction) Insider: Meyers James R (Director)

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 2 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Vera Therapeutics, Inc. has 2 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-02

VERA Form 144 filed for proposed insider sale

An insider at Vera Therapeutics, Inc. filed a Form 144 notifying the SEC of an intent to sell shares. Form 144 is a proposed sale notice rather than confirmation that a sale already happened.

Filing: Form 144 (Proposed Sale Notice)

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-23

VERA Form 144 filed for proposed insider sale by MARSHALL FORDYCE (74,000 shares) ~$2.84M

MARSHALL FORDYCE filed a Form 144 with the SEC indicating intent to sell VERA (Vera Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: MARSHALL FORDYCE Shares: 74,000 Est. Value: $2.84M

View on SEC EDGAR → Open Filing Document →

Material Events 6 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 6 in this period for Vera Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-15